NY-AQARA
11.7.2022 09:02:05 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, announced the wide availability of its Curtain Driver E1, a retrofit solution to automate traditional curtains. Build upon the Zigbee 3.0 protocol with improved reliability, range and energy efficiency, the curtain driver features a battery life of up to 12 months between each charge1 , and connects with other smart home accessories to enable truly automated home experiences2 . The Curtain Driver E1 has been made available on Amazon in both North America (US , Canada ) and Europe (UK , France , Germany , Italy , Spain ), as well as via selective Aqara retailers worldwide3 .
With two variants, namely the Rod Version for rods and the Track Version for U-rails and I-rails, the Aqara Curtain Driver E1 are compatible with a majority of curtains on the market. Thanks to its quiet-yet-powerful motor, heavier curtains of up to 12 kilograms can be pulled. It also features a wide compatibility with third-party ecosystems and voice assistants, including HomeKit/Siri, Alexa, Google Home/ Google Assistant, IFTTT, and the upcoming Matter standard will also be supported after its roll-out4 .
The installation is easy. Just mount the Curtain Driver E1 onto the curtain rod or rail, and no additional tools are required. The retrofit solution requires no new wiring to motorize the curtains, and the 6000mAh battery - which lasts for up to 1-year of use - can be charged via the Type-C port. It’s equipped with a built-in light sensor, allowing the curtain to close by its own when it’s too bright, and vice versa.
Apart from ambient brightness, the Curtain Driver can also be smartly controlled by other conditions, such as pre-set schedules, sunrise/sunset, local weather, and geofencing. For example the curtains open at sunset so that the beautiful view won’t be missed. When connect with other Aqara devices, more possibilities are made possible. Use a Wireless Mini Switch to open, close or stop the curtain by a simple press, or adjust the precise opening by turning the Cube. The Camera Hub G3 even allows the curtain to be controlled with hand gestures.
The Curtain Driver is designed with high flexibility to suit for different scenarios and use cases. Device grouping is supported, so that double sided curtains can be controlled simultaneously. The speed of the curtain driver is adjustable, and the device can be configured to work more quietly in the mornings so that the sleep won’t be interrupted anymore. Moreover, it’s possible to set the duration time for curtain movements, for example to pull the curtain from closed to fully open in an hour, which simulates a natural sunrise.
In celebration of the launch, Aqara now offers a 20% discount for the new device on Amazon. North American customers will enjoy the offer with the promo code USCURTAIN in the US and Canada , while European customers will enjoy it using the promo code CURTAINUKEU in France , Germany , Italy , Spain and the UK . Both codes are valid on July 11th , 2022. And Amazon Prime members will continue to enjoy the discount from July 12th to 13th with no promo code required.
For more details of the Curtain Driver E1, please visit our website .
1. Based on the lab test of two devices on the double panel curtains. The actual battery life may vary, depending on curtain weight, track length, and friction.
2. A Zigbee 3.0 Aqara hub is required.
3. Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the regional retailer(s) for real time availability.
4. An OTA update of the compatible Aqara hub is required.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005076/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom